Compare Pfizer Inc (PFE) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Snowflake Inc — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Snowflake Inc trades at $345.15 (market cap $117.43B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.14% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Snowflake Inc for 54 Days on average.
| PFE | SNOW | |
|---|---|---|
Market Cap | $159.59B | $117.43B |
Volume | 30,937,010 | 2,441,528 |
Sector | Health | Technology |
52-Week High | $29.02 | $356.47 |
52-Week Low | $23.67 | $121.11 |
Typical Hold Time | 158 Days | 54 Days |
Enterprise Value | $211.09B | $117.85B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SNOW trades at $343.4, up 2.22% on the day, with a neutral technical signal and bullish moving averages. Revenue growth is strong, reaching $3.63B in 2025, but the company remains unprofitable with a net income margin of -20.07%. Recent news highlights a $3.75B convertible note offering and positive analyst coverage, with 81% of analysts rating it a Buy and a consensus price target of $418.03.
The outlook is mixed: robust revenue expansion and strategic partnerships offer upside, but persistent losses, high valuation multiples, and dilution risks from the note issuance pose significant challenges. Investor sentiment is cautiously optimistic, hinging on future profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
